Latest Conference Articles

December 10th 2012, 9:57am

San Antonio Breast Cancer Symposium

Photos from the 35th annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), held at the Henry B. Gonzalez Convention Center, San Antonio, TX, from December 4-8, 2012.

December 10th 2012, 8:54am

ASH Annual Meeting and Exposition

Researchers have demonstrated that ponatinib can overcome a wide range of mutations that cause treatment resistance-including the stubborn T315I mutation-in all stages of CML and Ph+ ALL.

December 10th 2012, 7:24am

ASH Annual Meeting and Exposition

The combination of pomalidomide and a steroid significantly improved outcomes for patients with MM who have exhausted other novel therapies, marking what researchers say is a notable advancement for a sizable proportion of those treated for the disease.

December 10th 2012, 7:00am

ASH Annual Meeting and Exposition

MLN9708 has shown comparable efficacy and greater convenience and tolerability than bortezomib, for patients with multiple myeloma.

December 9th 2012, 3:05pm

ASH Annual Meeting and Exposition

Harry Erba, MD, PhD, professor of medicine and director, University of Alabama at Birmingham Hematologic Malignancy Program, explains the declining treatment-related mortality (TRM) rates in AML patients.

December 9th 2012, 2:18pm

ASH Annual Meeting and Exposition

Tiziano Barbui, MD, USC Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy, on hematocrit (HCT) levels in patients with polycythemia vera (PV).

December 9th 2012, 2:03pm

ASH Annual Meeting and Exposition

Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic, talks about managing toxicities in the MLN9708 study.

December 9th 2012, 8:21am

ASH Annual Meeting and Exposition

The novel targeted agent ibrutinib has demonstrated dramatic activity in hard-to-treat patients with CLL when used alone and in combination with rituximab.

December 9th 2012, 8:00am

ASH Annual Meeting and Exposition

Researchers have identified a genetic profile of the patients who are most likely to develop congestive heart failure after being treated with anthracyclines and then undergoing hematopoeitic stem cell transplant (HCT) for a range of blood cancers.

December 8th 2012, 5:36pm

San Antonio Breast Cancer Symposium

The mental toll and stress of a breast cancer diagnosis might factor into the cognitive impairment experienced during chemotherapy treatment, commonly referred to as "chemo brain."

December 8th 2012, 5:14pm

San Antonio Breast Cancer Symposium

Christopher Twelves, MD, discusses results from a phase III trial that compared capecitabine to eribulin mesylate in women with metastatic breast cancer.

December 8th 2012, 11:14am

ASH Annual Meeting and Exposition

John C. Byrd, MD, director of the division of hematology at The Ohio State University Comprehensive Cancer Center, discusses the new and updated results of a phase Ib/II study involving ibrutinib at the ASH Annual Meeting and Exposition.

December 8th 2012, 9:26am

San Antonio Breast Cancer Symposium

Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, discusses research into clinically targetable genetic alterations in patients with triple-negative breast cancer.

December 7th 2012, 5:33pm

San Antonio Breast Cancer Symposium

Long-term follow-up results showed that the hypofractionated regimens were as effective as the 50-Gy standard in women with early-stage breast cancer.

December 7th 2012, 3:57pm

San Antonio Breast Cancer Symposium

Eight-year follow-up data from the phase III HERA trial has confirmed that 1-year of adjuvant trastuzumab should remain the treatment standard in women with HER2-positive early-stage breast cancer.

December 7th 2012, 3:33pm

San Antonio Breast Cancer Symposium

John Yarnold, MBBS, from The Institute of Cancer Research in London, discusses results from the START trials that examined hypofractionated radioatherapy for women with early breast cancer.

December 7th 2012, 2:47pm

San Antonio Breast Cancer Symposium

Patients with triple-negative breast cancer had no statistically significant improvement in disease-free survival when they received adjuvant treatment with chemotherapy plus 1 year of bevacizumab.

December 7th 2012, 12:50pm

San Antonio Breast Cancer Symposium

Brian Leyland-Jones, MBBS, PhD, discusses results from the phase III HERA trial that compared 2 years of adjuvant trastuzumab to the standard 1 year in HER2-postive early-stage breast cancer.

December 7th 2012, 12:25pm

San Antonio Breast Cancer Symposium

Eribulin mesylate failed to show a statistically significant survival benefit compared with capecitabine in women with previously treated metastatic breast cancer.

December 6th 2012, 4:37pm

San Antonio Breast Cancer Symposium

Patients with triple-negative breast cancer who have residual disease after receiving neoadjuvant chemotherapy have a series of genetic alterations that are clinically targetable and may warrant further study.